Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses

NCT07635654 | Not Yet Recruiting

• 1 other identifier: S71975
• Study Type: interventional
• Target: 43
• Locations: 0 countries
• Sites: N/A

Brief Summary

Metastatic invasive lobular carcinoma (ILC) is a distinct breast cancer subtype characterized by loss of E-cadherin and a diffuse growth pattern that makes metastases difficult to detect with standard imaging such as computed tomography (CT) or 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)/CT. As a result, disease burden in patients with ILC is frequently underestimated, progression is identified later than clinically optimal, and many patients are excluded from clinical trials due to insufficiently measurable disease. Whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) is a radiation-free imaging technique that has demonstrated improved sensitivity for detecting metastases-including peritoneal, bone, and nodal disease-in ILC. Retrospective studies suggest that WB-DWI/MRI can identify clinically relevant progression not visible on standard imaging. However, prospective evidence in ILC is lacking. Circulating tumor DNA (ctDNA) has also shown promise as a minimally invasive biomarker for monitoring treatment response, with early molecular changes often preceding radiologic progression, but data specific to ILC remain limited. The DELILA study is a prospective, multicenter clinical trial conducted at University Hospitals Leuven and Institut Jules Bordet. The study aims to enroll 43 patients starting first-line systemic therapy for metastatic hormone receptor positive human epidermal growth factor receptor 2 negative (HR+/HER2-) ILC. Participants undergo serial dual imaging-WB-DWI/MRI and standard-of-care imaging-at baseline, at 1 month, and approximately every 3 months for up to 30 months or until disease progression. At each imaging time point, blood samples are collected for ctDNA analysis and Ca15.3 tumor marker assessment. Patient-reported psychological burden related to repeated imaging and blood sampling is evaluated using validated questionnaires. The primary objective is to assess the added value of WB-DWI/MRI in detecting disease progression that informs clinical decision-making compared to standard imaging. Secondary objectives include evaluating whether ctDNA or Ca15.3 dynamics reflect disease evolution, assessing measurability of lesions with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and MRI-specific criteria, identifying early biomarkers of treatment response using Apparent Diffusion Coefficient (ADC) changes and ctDNA kinetics, and characterizing the psychological impact of trial procedures. This study will provide the first adequately powered prospective evidence on the clinical utility of WB-DWI/MRI and liquid biopsy monitoring in metastatic ILC. Results may support implementation of WB-DWI/MRI as a routine imaging strategy, guide imaging frequency through biomarker-informed approaches, and improve patient experience and trial eligibility for individuals living with metastatic ILC.

Conditions

Invasive Lobular Breast Carcinoma

Keywords

Invasive lobular carcinoma; Imaging; WB-DWI MRI; Liquid biopsy

Outcome Measures

Primary Outcomes (1)

• Percentage of cases where WB-DWI/MRI contributed solely to the decision of progression and/or treatment change assessed by questionnaires filled out by the treating oncologist at the time of progression

  At the time of progression

Secondary Outcomes (7)

• ctDNA dynamics

  At baseline, after 1 month of treatment, and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).

• Measurability according to RECISTv1.1 criteria

  At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).

• Measurability according to MRI-specific criteria

  At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).

• Disease extent on WB-DWI/MRI compared to SOC imaging

  At baseline and every 3 months of treatment until disease progression or a maximum follow-up of 30 months (end of trial).

• Lesion-level ADC dynamics

  At baseline and after 1 month of treatment

Study Arms (1)

Standard-of-care Imaging + Whole-body diffusion-weighted MRI

EXPERIMENTAL

Participants will undergo dual imaging at baseline and then every three months during first-line treatment for metastatic ILC, continuing until either 30 months of follow-up or documented disease progression. At these same timepoints, ctDNA levels and Ca15.3 will also be assessed.

Diagnostic Test: whole body diffusion weighted MRI; Diagnostic Test: ctDNA

Interventions

whole body diffusion weighted MRI DIAGNOSTIC_TEST

Frequency: at baseline, after 1 month and every 3 months until 30 months of follow-up or disease progression

Standard-of-care Imaging + Whole-body diffusion-weighted MRI

ctDNA DIAGNOSTIC_TEST

Frequency: at baseline, after 1 month and every 3 months until 30 months of follow-up or disease progression

Standard-of-care Imaging + Whole-body diffusion-weighted MRI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
• At least 18 years of age at the time of signing the Informed Consent Form (ICF)
• ECOG from 0 to 2
• Patient with stage IV ILC, either de novo or after prior (curative) treatment for early ILC. Histological subtype confirmed on primary tumor or on metastatic tissue. Patients that are diagnosed with stage IV breast cancer that have a mixed ILC/IBC-NST histology of the primary tumor (mixed histology within the same primary lesion) will also be able to participate and will be analyzed in an exploratory cohort.
• Confirmation of hormone receptor positive (HR+)/HER2- disease either on new biopsy or archival tissue (e.g. primary tumor)
• Multifocal or bilateral disease is allowed if all evaluated foci present with HR+/HER2- ILC
• Starting first line of treatment for metastatic ILC

You may not qualify if:

• Presence of a contraindication to perform WB-DWI/MRI
• Presence of severe claustrophobia
• Presence of a contraindication to use IV contrast for CT or PET/CT (e.g. allergy, severe renal failure) in case a non-contrast PET/CT cannot be performed
• Patients considered to have oligometastatic disease who are expected to undergo locoregional treatment
• Presence of other malignancies in recent medical history (\<5 years)
• Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
• Adults who are the subject of a legal protection measure or who are unable to express their consent.

Sponsors & Collaborators

• KU Leuven: lead
• Jules Bordet Institute: collaborator

MeSH Terms

Conditions

Carcinoma, Lobular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Ductal, Lobular, and Medullary; Breast Neoplasms; Neoplasms by Site; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Hans Wildiers, MD/PHD

  UZ Leuven

  PRINCIPAL INVESTIGATOR

• Philippe Aftimos, MD

  Jules Bordet Institute

  PRINCIPAL INVESTIGATOR

• Elia Biganzoli, PHD

  University of Milan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: May 27, 2026
• First Posted: June 9, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): June 30, 2030
• Study Completion (Estimated): June 30, 2030
• Last Updated: June 9, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share